Nanjing Leads Biolabs Co., Ltd.
Research Nanjing Leads Biolabs Co., Ltd. (9887.HK) on Bullrun: market cap HKD 8.21B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker9887.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 8.21B
- Financial periodQ2 2025
- RevenueCNY 0
- Net income-CNY 91.03M
Valuation Snapshot
latest market cap is HKD 8.21B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 8.21B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Nanjing Leads Biolabs Co., Ltd.
Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialization of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company's lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma; LBL-007, a novel anti-LAG-3 antibody designed to restore T-cell activity; LBL-034, a novel GPRC5D-targeting T-cell engager for anti-tumor activity.
ETFs that hold Nanjing Leads Biolabs Co., Ltd.
US-listed ETFs
Nanjing Leads Biolabs Co., Ltd. is held by 2 US-listed ETFs, going by the latest portfolios they filed with the SEC, most traded first:
| ETF | Weight | Fee |
|---|---|---|
| State Street SPDR Portfolio MSCI Global Stock Market ETF (SPGM) | <0.01% | 0.09% |
| iShares MSCI China Small-Cap ETF (ECNS) | 0.15% | 0.59% |
Portfolios as filed with the SEC on Form N-PORT, dated May to June 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Nanjing Leads Biolabs Co., Ltd.'s market cap?
Nanjing Leads Biolabs Co., Ltd.'s market capitalization is HKD 8.21B.
What does Nanjing Leads Biolabs Co., Ltd. do?
Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialization of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company's lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma; LBL-007, a novel anti-LAG-3 antibody designed to restore T-cell activity; LBL-034, a novel GPRC5D-targeting T-cell engager for anti-tumor activity.